Having trouble accessing articles? Reset your cache.

Vyvanse lisdexamfetamine dimesylate: Development discontinued

Shire disclosed in its 1Q13 earnings that it discontinued development of lisdexamfetamine dimesylate for negative symptoms of schizophrenia "after a review and prioritization"

Read the full 239 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE